How to Register a Medicine in Egypt: The Complete 2026 Guide
What EDA requires, how the process works, and the most common reasons registrations fail.
Registering a pharmaceutical product in Egypt requires submission of a complete registration dossier to the Egyptian Drug Authority (EDA). The process is structured, technically demanding, and typically takes 12–36 months from first submission to approval depending on the product type and dossier quality. This guide covers the requirements, the process, the most common reasons for rejection or delay, and how EMCO Egypt manages registration dossiers.
Dossier format: the CTD structure
EDA accepts registration dossiers in Common Technical Document (CTD) format, with an increasing range of product types now requiring electronic CTD (eCTD) format. The CTD is structured across five modules:
- Module 1 — Regional / Administrative: Application form, Arabic labelling (SmPC, PIL, labels), regulatory status in other countries. Egypt-specific; must be tailored to EDA's requirements.
- Module 2 — Summaries: Expert summaries of quality, non-clinical, and clinical data.
- Module 3 — Quality: API and finished product manufacturing, characterisation, control, stability data. Typically the largest module.
- Module 4 — Non-Clinical: Pharmacology, pharmacokinetics, and toxicology. For generics, bibliographic references are typically acceptable.
- Module 5 — Clinical: Bioequivalence data comparing the generic to the EDA reference product.
EDA-specific requirements
- Arabic labelling — Mandatory. SmPC, PIL, and labels in Arabic (or bilingual), complying with EDA content and formatting requirements.
- Local agent — Foreign manufacturers must appoint a registered Egyptian local agent. Agent registration must be current at the time of application.
- GMP recognition — EDA accepts inspection by reference authorities (FDA, EMA, SFDA, and others on EDA's recognised agency list) in lieu of direct site inspection.
- Bioequivalence study — Required for generic pharmaceutical products, comparing the generic to the Egyptian-market reference product, conducted to ICH E6 GCP standards.
- Pricing approval — Egyptian pharmaceutical pricing is controlled. Price must be approved by EDA's pricing committee before a registered product can be marketed.
The registration process: step by step
1. Dossier Preparation
3–9 months. Assembling a complete, compliant CTD dossier. For products already registered elsewhere, this means adapting the existing dossier to EDA's specific requirements.
2. Submission & Admin Review
EDA confirms the dossier contains all required components. Missing components trigger a deficiency list. Responding promptly is critical — delays extend the overall timeline.
3. Technical Review & Approval
EDA reviews quality, non-clinical, and clinical data, and may issue technical queries. On completion, EDA issues the registration certificate. Total timeline: 18–30 months for well-prepared generic dossiers.
Common reasons for delays and rejections
- Incomplete Module 1 — Missing Arabic labels, absent local agent documentation, or expired GMP certificate.
- Bioequivalence study not accepted — Wrong comparator, protocol not meeting ICH E6, or statistical approach not aligned with EDA's current guidance.
- Module 3 quality gaps — Stability data not covering Egypt's climate Zone IVb (40°C / 75% RH), or manufacturing site documentation not current.
- Labelling non-compliance — Arabic labels not meeting EDA content or formatting requirements.
- Late response to EDA queries — Missing EDA's query response window results in dossier closure and requirement to resubmit.
How EMCO Egypt manages registration dossiers
EMCO Egypt prepares and submits registration dossiers for Egyptian and international pharmaceutical companies — managing the full process from dossier gap assessment through to market approval. For eCTD format submissions, we use eCTD Radar — our EMA R2 and R3 validated dossier software. For active portfolios, Reg Radar provides real-time tracking of all registration milestones and renewal deadlines. For African and Gulf registrations, the same registration outsourcing service extends via Pharmagit and eCTD Radar respectively. Learn more about EMCO Egypt or contact us.
Common Questions About EDA Registration
EDA's eCTD requirements are expanding. For a growing range of product types and submission categories, eCTD format is now required or strongly preferred. Companies planning Gulf or European submissions alongside Egyptian registration benefit from building eCTD capability from the start.
Egypt falls in ICH climate Zone IVb — hot and humid (40°C / 75% relative humidity). Stability data submitted to EDA must cover Zone IVb conditions. Products with only Zone II stability data (25°C / 60% RH, used for European submissions) are a common source of Module 3 deficiency findings.
Yes. EMCO Egypt manages the full post-approval lifecycle — renewals, Type I and Type II variations, and labelling updates. Reg Radar tracks all deadlines for products in a client's portfolio, ensuring no registration lapses due to a missed deadline.
Ready to register your product in Egypt?
EMCO Egypt manages EDA dossier registration from gap assessment through to market approval.
Request a Registration Assessment Registration Services